Collaboration opportunities

Our label-free photonic biosensor technologies have demonstrated outstanding performances for rapid, highly sensitive, and reliable detection of all kind of biomarkers in clinical diagnostics and therapy monitoring. We are open to collaborations with clinical and biomedical partners interested to introducing novel technologies in their fields to boost and improve bioanalysis.

I am working in Artifical Intelligence and Big Data research field in Maastricht University , Institute of Data Science.
My goal is to use AI and Big data software and system we develop for analyzing information from Social Networks Offical Data resources. I would like to use these resources with state of the art natural language processing and image processing models. I have previous experience in digital forensics using Big data therefore using this background I aim to provide tools to investigate effects of COVID on society economy and businesses.

I am looking forward to meeting with possible partners for developing analysis projects, who can identify health, social, economical business or other problems. Then we can provide early alarms and come up with solutions and publish our findinds.

I am working in nano drug design field in Altınbaş University , Faculty of Pharmacy.
My goal is to use nanoformulations we develop for enhancing bioavailability. I also use these formulations for fluorescent imaging and side effects. I have previous experience in olmesartan medoxomil SMEDDS and Dexamethasone SNEDDS ophtalmic gtt. I aim to design new formulations with this technology for miRNA's and vaccines.

I am looking forward to meeting with possible partners for drug development projects, who has bioavailability, side effect and drug targeting problems. Then we can provide solutions and publish our findings.

Eligibility criteria
Researchers in R&D fields from universities, public or private sector.

I am working in nano drug design field in Altınbaş University , Faculty of Pharmacy.
My goal is to use nanoformulations we develop for enhancing bioavailability. I also use these formulations for fluorescent imaging and side effects. I have previous experience in olmesartan medoxomil SMEDDS and Dexamethasone SNEDDS ophtalmic gtt. I aim to design new formulations with this technology for miRNA's and vaccines.

I am looking forward to meeting with possible partners for drug development projects, who has bioavailability, side effect and drug targeting problems. Then we can provide solutions and publish our findings.